U.S. Markets close in 6 hrs 11 mins

Incyte Has Diversified Its Revenues across Multiple Product Lines

Margaret Patrick
Incyte Has Diversified Its Revenues across Multiple Product Lines

Incyte (INCY) expects to report GAAP (generally accepted accounting principles) and non-GAAP revenues in the range of $80 million to $85 million from the sale of Iclusig in fiscal 2018. In June 2016, Incyte entered a licensing agreement with Ariad Pharmaceuticals for the development and commercialization of kinase inhibitor, Iclusig, in the European Union and 22 other countries.